Venus Remedies: How We Underwrote It, and What FY26 Confirmed
A reasonable price on current numbers protected the downside. The optionality did the rest. This is a live case study in how we work.
We first wrote up Venus Remedies a little over a year ago, in our deep dive Innovation, Turnaround, and Asymmetry, and followed it with a detailed read of a decade of annual reports in our Annual Reports Analysis. At the time, the stock was trading at around Rs 450, a marketcap of roughly Rs 600 crore. The company has just reported its FY26 audited numbers. The market capitalisation today is around Rs 1,500 crore.
The 2.5x in under a year is not the point of this post. We are writing this one as a case study, because Venus is a clean, real-time example of the way we try to operate. If you want to understand the Nine One Capital process, this is a better teacher than any framework post we could put together.
So we are going to do three things here. First, walk through what we were actually underwriting when we bought it. Second, show what FY26 confirmed, where the P&L is amazing but the balance sheet and cash flow are the real story. Third, lay out why we are still holding after the move.
Why we were buying Venus a year ago
When we bought Venus, the trailing twelve month profit after tax was about 45 crore. At a marketcap of 600 crore, we were paying a little over 13 times trailing earnings for the business as it stood. Reasonable starting valuations matter to us more than anything else we are about to say, so we want to be explicit about it. We were not paying for a story. We were paying a reasonable multiple for a business that was already profitable, already generating cash, and already most of the way through cleaning up its balance sheet.
What we saw underneath that price was a company part way through a genuine transition that the market had not yet rewarded:
The balance sheet became debt free. A company that had spent years known for financial stress was about to carry no debt at all.
Operating cash generation was already strong and rising, which told us the reported profits were real and not an accounting artefact.
Our read of ten years of annual reports showed a clear and steady shift in tone, from the defensive language of a company trying to survive to the measured confidence of one that was beginning to scale. We documented this shift in detail in our annual report note. Tone in annual reports is soft data, but read across a decade it is one of the more honest signals a management team gives off, because it is hard to fake consistently.
On top of all of that sat a set of optionalities we were paying nothing for: a research pipeline in anti-microbial resistance led by VRP-034, an in-licensed asset in MET-X, a deliberate product mix shift toward higher margin oncology, and early institutional wins with bodies like UNICEF and PAHO. All of these are discussed in the substack post which we posted last year in July (link)
That last group is the part most investors either ignore or overpay for. We did neither. We bought the business on its current numbers, where the multiple protected us on the downside, and we treated the pipeline, the mix shift, and the expansion plans as free call options on the upside.
Why this is how we work
This is the structure we look for in almost everything we own. A business that is reasonable, or better, on the numbers it is printing today, so that the downside is anchored by something real. And a set of catalysts on top of that, growth plans, strategic shifts, optionality, that we are not paying much or anything for, which can drive the re-rating and the margin expansion if they play out.
When the catalysts work, you get the kind of move Venus has given us. When they do not, you are still left holding a profitable business bought at a sensible price, which is a very different outcome from holding a story that has stopped working.
We want to draw the contrast sharply, because the rest of the market is currently doing the opposite. Capital today is crowding into data centres, the AI value chain, and a handful of related narratives. Several of these are genuinely good businesses with real tailwinds. The problem is the price. To own most of these names today you are asked to pay a multiple that already discounts the next five to ten years of profit and cash flow. The thesis rests almost entirely on narrative, and the return increasingly depends on finding the next buyer willing to pay an even higher multiple.
We were asked exactly this at a recent investor event, where we had presented Kaveri Seeds. The question was Why were we not bringing forward an idea from one of the themes in Aerospace, Defence, AI, Data centre etc. which everyone is excited about. The paragraph above is more or less the answer we gave. We have nothing against those themes. We have a problem with paying a price that needs everything to go right for a decade just to earn a fair return, in a situation where our entire edge would reduce to guessing who the next buyer is. That is not a game we play well, and it is not one we need to play.
Q4 FY26 and Full Year Results
The P&L growth is real, and the two tables below set it in context. A good P&L is only half of what we like. The balance sheet and the cash flow statement are what genuinely impress us here, and they are the larger reason we are comfortable continuing to hold after the move.
Looking at the balance sheet, debt is now nil. The company that the market once associated with financial stress now carries zero debt.
Now look at the quality of the growth. The company grew revenue by close to 18%, and yet trade receivables in absolute terms actually fell, from 112 crore to 103 crore. Growing the top line while shrinking your receivables is the opposite of what most companies do when they chase growth, and it is one of the cleanest signals of pricing power and disciplined collection that we look for. It flows straight through to cash.
Net cash from operating activities for FY26 was 155 crore, higher than the EBTIDA it generated. This is the second consecutive year of operating cash flow exceeding reported EBITDA.
The result of all this is that the company now sits on over 250 crore of cash and investments with no debt against it. This gives the company a strong source of capital to undertake their expansion plans and R&D efforts. Management has been clear during AGMs and in the annual reports, that they intend to expand capacity, particularly in lyophilisation where they currently serve only about half the demand they see, and that they are evaluating greenfield projects. A debt free company throwing off 150 crore of operating cash a year, sitting on a 250 crore plus war chest, can fund that expansion internally, can pursue an acquisition if the right one appears, and can do all of it without diluting shareholders or taking on leverage. That is the optionality the balance sheet itself creates, quite apart from the research pipeline.
The pipeline is still a free option, and we mean free
The research pipeline is where the long term asymmetry sits, and it is worth being precise about how we think about it, because it is easy to get this wrong in either direction.
R&D optionality in pharma is real, and when it crystallises it can be enormous. It is also lumpy, unpredictable, and almost completely invisible in the quarterly numbers until the moment it is not. The clearest recent illustration is SPARC. For most of FY26 it was a clinical stage research company burning cash, with quarterly revenue of just ₹8.4 crore and a net loss of ₹ 80.4 crore in Q3 FY26. Then a single event changed the whole year. SPARC swung to a full year net profit of about ₹1,552 crore, driven by the sale of a Priority Review Voucher for USD 195 million, which alone contributed roughly ₹1,840 crore to revenue. Years of losses, and then one R&D asset monetised in a single stroke that dwarfed everything that came before.
We are not drawing that comparison to suggest Venus is about to do the same. We are drawing it to make a point about how to value a pipeline. Venus has a differentiated AMR platform in VRP-034, an in-licensed metallo-beta-lactamase inhibitor in MET-X, and other early stage work. Any one of these, if it lands, could be transformational.
None of it is in our thesis as a base or bull case. We underwrote Venus on the business as it stood, and we continue to value it on the business as it stands. The pipeline is a call option we paid nothing for. It is optionality, and nothing more, and we are deliberately keeping it that way in our own model. That is the discipline that lets us hold it without ever depending on it.
Valuation after a 2.5x move
Here is the part that we suspect will surprise readers who assume a 2.5x move must have left the stock expensive.
After moving from roughly 600 crore to around 1,500 crore, Venus today trades at under 15 times TTM PAT and around 9 times EV to EBITDA. Considering how the P&L has performed, the entire return came from earnings more than doubling, not from the market paying a higher multiple. That is the most durable kind of return there is, and it is precisely why we are still comfortable here. A re-rating driven by multiple expansion is borrowed from the future. A re-rating driven by earnings is earned, and it leaves the door open for the multiple to expand later, which it has not yet done.
We are continuing to hold, for three reasons that stack on top of each other. The first is the broad pharma theme, where injectables and AMR are structurally well positioned and Venus is a credible, accredited, second ranked player in India in parts of its mix. The second is the research pipeline optionality, which we are carrying at zero. The third is the expansion that the balance sheet can now fund on its own.
Two more signals reinforce the read. The company has declared a dividend for the first time in thirteen years. A first dividend after that long a gap is not about the yield. It is a statement of intent from the promoter group about the company’s financial footing and their confidence in it. And at around 1,500 crore, with the free float now at a size that domestic institutions can actually build a position in, Venus has crossed the threshold from a name too small for most professional money to look at, into one that institutional investors can begin to own. That is a change in the buyer base that tends to matter.
What we are doing, and what comes next
We continue to hold Venus. We are not chasing it higher with aggressive buying at these levels, but we are not trimming a business that is compounding earnings, generating cash, and carrying optionality we paid nothing for. The thesis we wrote a year ago has played out faster than our base case, and the parts that have not yet played out, the pipeline and the next wave of capacity, sit ahead of us.
Writing about a position that has worked is the easy part. Everyone enjoys it, ourselves included. But it is not where the real work of this job is done.
In our next post, we are going to write about the other side of the book. We will talk about stocks we own that have disappointed on results, and how we are thinking about them. When a holding underperforms, the only question that matters is whether the original thesis is still intact. If it is, that is often where the incremental IRR is hiding, because you can add to a sound business at a lower price while everyone else is selling the screen. If it is not, you cut it. Working through that distinction honestly, in public, and managing our own expectations and our clients’ through it, is where the alpha in this segment actually comes from. We will get into it next week.
At Nine One Capital, we spend a significant amount of time building the right analytical foundation before forming a view on any company. If you would like to understand our research process in more depth or explore how our advisory services can support your investment journey, you can reach us at gaurav.a@nineonecapital.in or fill in the form here (link).
Important Note and Disclaimer: Nine One Capital is a SEBI Registered Investment Adviser (Registration No. INA000018814). This article is not a buy/sell recommendation. We are simply highlighting a potentially mispriced opportunity based on publicly available data. We could be wrong, and investors must do their own due diligence before taking any position. Please note that this note is shared only for the education purpose and in no way, it constitutes any buying or selling recommendation. We and our clients hold a position in Venus Remedies and may transact in it. Past performance is not indicative of future returns.
Perfect. "Heads I win, tails I don't lose much"
Very insightful. Simple to understand.